Edition:
United States

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

46.84USD
4:00pm EDT
Change (% chg)

$-0.89 (-1.86%)
Prev Close
$47.73
Open
$47.57
Day's High
$48.36
Day's Low
$46.47
Volume
59,193
Avg. Vol
41,923
52-wk High
$68.91
52-wk Low
$17.07

Chart for

About

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for... (more)

Overall

Beta: --
Market Cap(Mil.): $738.57
Shares Outstanding(Mil.): 15.47
Dividend: --
Yield (%): --

Financials

  URGN.OQ Industry Sector
P/E (TTM): -- 214.97 33.20
EPS (TTM): -2.31 -- --
ROI: -- -3.79 13.23
ROE: -- -5.32 15.28

Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

Jun 21 2018

INTERVIEW-Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel, June 21 Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

Jun 21 2018

BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101

* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)

May 21 2018

BRIEF-UroGen Pharma Reports Q1 Loss Per Share Of $0.88

* UROGEN PHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

May 15 2018

BRIEF-Urogen Pharma Reports Q4 Loss Per Share Of $0.74

* UROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Urogen Pharma Announces Pricing Of Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

Jan 18 2018

Earnings vs. Estimates